Categories AlphaGraphs, Earnings, LATEST, Retail

TJX Companies misses Q2 sales expectations; EPS in line with estimates

The TJX Companies Inc. (NYSE: TJX) missed sales estimates for the second quarter of 2020 while earnings matched expectations. The stock was down 3% in opening hours on Tuesday.

Net sales rose 5% year-over-year to $9.8 billion but fell short of forecasts of $9.9 billion. Consolidated comp sales increased 2%, driven mainly by customer traffic, compared to a 6% increase last year.   

TJX Companies missed sales estimates while earnings matched expectations for the second quarter of 2020

Net income was $758 million, or $0.62 per share, compared to $739 million, or $0.58 per share, in the prior-year quarter. The consensus estimate was for EPS of $0.62.

During the quarter, TJX Companies posted net sales increases across all four of its divisions. Comp sales grew in the low to mid single-digit range across all segments, except HomeGoods US. Customer traffic increased in all four divisions.   

Gross profit margin was 28.2%, down 0.7% from last year, in line with the company’s guidance. The decline was mainly caused by a decrease in merchandise margin and higher supply chain costs.

Also see: TJX Companies Q1 2020 Earnings Report

Total inventories at quarter-end were $5.1 billion, compared with $4.5 billion in the same period last year. Consolidated inventories on a per-store basis, including the distribution centers, but excluding inventory in transit, the company’s e-commerce sites, and Sierra stores, increased 6% on a reported basis, and 7% on a constant currency basis. 

During the second quarter, TJX Companies increased its store count by 31 stores to a total of 4,412 stores. The company increased square footage by 4% to 118.4 million.

For the third quarter of 2020, TJX Companies expects EPS to be $0.63-0.65. Comparable store sales is estimated to grow 1-2% both on a consolidated basis and at Marmaxx.

For fiscal-year 2020, the company expects EPS of $2.56-2.61, reflecting a 5-7% increase over last year. Comparable store sales is projected to grow 2-3% on a consolidated basis and at Marmaxx.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top